Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer

Considerations for the approach to HRRm testing in prostate cancer

Date

22 Sep 2020

Session

AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer

Presenters

Alexander Wyatt

Authors

A.W. Wyatt

Author affiliations

  • University of British Columbia, Vancouver/CA
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings